These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14760059)

  • 1. Overcoming methodological weakness in dose-intense alkylating agent studies through pharmacology.
    Jones RB
    Clin Cancer Res; 2004 Jan; 10(2):413-4. PubMed ID: 14760059
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between two alkylating agents: CB 3210 and cyclophosphamide.
    Schmidt-Ruppin KH
    Oncologia; 1965; 19(4):285-93. PubMed ID: 5864377
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent advances in the biochemical pharmacology of selected alkylating agents.
    Wheeler GP
    Transplant Proc; 1973 Sep; 5(3):1167-70. PubMed ID: 4738047
    [No Abstract]   [Full Text] [Related]  

  • 5. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide, 2,2-dimethylaziridines and other alkylating agents as inhibitors of serum cholinesterase.
    Lalka D; Bardos TJ
    Biochem Pharmacol; 1975 Feb; 24(4):455-6. PubMed ID: 1167458
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.
    Gerhartz HH; Liss E; Schmidt H
    J Cancer Res Clin Oncol; 1979 Jul; 94(3):257-63. PubMed ID: 479265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategy and alternate randomized designs in cancer clinical trials.
    Zelen M
    Cancer Treat Rep; 1982 May; 66(5):1095-100. PubMed ID: 7083213
    [No Abstract]   [Full Text] [Related]  

  • 9. Alkylating agents.
    Connors TA
    Cancer Chemother Biol Response Modif; 1992; 13():31-44. PubMed ID: 1389913
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of alkylating agents on the embryonal development].
    Knörr K; Knörr-Gärtner H; Uebele-Kallhardt B
    Geburtshilfe Frauenheilkd; 1969 Jul; 29(7):601-11. PubMed ID: 5256974
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunosuppression through alkylating agents: hints on the superiority of 5122 ASTA to cyclophosphamide].
    Botzenhardt U; Lemmel EM
    Verh Dtsch Ges Inn Med; 1975; 81():1191-3. PubMed ID: 1229436
    [No Abstract]   [Full Text] [Related]  

  • 12. Factorial designs for randomized clinical trials.
    Byar DP; Piantadosi S
    Cancer Treat Rep; 1985 Oct; 69(10):1055-63. PubMed ID: 4042085
    [No Abstract]   [Full Text] [Related]  

  • 13. The designs, control and pitfalls of clinical trials.
    Bramwell V
    Clin Otolaryngol Allied Sci; 1986 Dec; 11(6):397-401. PubMed ID: 3815864
    [No Abstract]   [Full Text] [Related]  

  • 14. An overview of cyclophosphamide and ifosfamide pharmacology.
    Fleming RA
    Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine.
    Eichbaum M; Bischofs E; Nehls K; Schneeweiss A; Sohn C
    Drugs Today (Barc); 2009 Jun; 45(6):431-44. PubMed ID: 19649333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methodological features of assessing the effectiveness of adjuvant therapy in clinical trials].
    Dvoĭrin VV
    Vopr Onkol; 1986; 32(6):18-22. PubMed ID: 3523991
    [No Abstract]   [Full Text] [Related]  

  • 17. [Sensitivity of the splenic cells of different mouse strains to the antiproliferative action of alkylating compounds].
    Pukhal'skiĭ AL; Mezhneva AP; Pevnitskiĭ LA
    Biull Eksp Biol Med; 1988 Feb; 105(2):196-8. PubMed ID: 3349150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alkylating agents on meningeal leukemia L1210 arising in methotrexate-treated mice.
    Chirigos MA; Humphreys SR
    Cancer Res; 1966 Aug; 26(8):1673-7. PubMed ID: 5923165
    [No Abstract]   [Full Text] [Related]  

  • 19. [THE TOTAL BLOOD ALKYLATING AGENT CONCENTRATION IN RATS AFTER ADMINISTRATION OF CYCLOPHOSPHAMIDE AND ACYCLOPHOSPHAMIDE].
    RAUEN HM; KRAMER KP
    Arzneimittelforschung; 1964 Sep; 14():1066-7. PubMed ID: 14344166
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cytomorphological changes in Escherichia coli cells exposed to alkylating compounds].
    Shved AD; Semernikova LI; Potopal'skiĭ AI; Tkachuk LV; Kitam OE
    Mikrobiol Zh (1978); 1982; 44(1):18-24. PubMed ID: 6803103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.